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Abstract
Background: There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection
or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector
based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4
recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120)
were evaluated.
Methods: The recombinant Ad4 vectors were generated with a full deletion of the E3 region of Ad4 to accommodate
the env gene sequences. The vaccine candidates were assessed in vitro following infection of A549 cells for Env-
specific protein expression and for posttranslational transport to the cell surface as monitored by the binding of
broadly neutralizing antibodies (bNAbs). The capacity of the Ad4Env vaccines to induce humoral immunity was
evaluated in rabbits for Env gp140 and V1V2-specific binding antibodies, and HIV-1 pseudovirus neutralization. Mice
immunized with the Ad4Env160 vaccine were assessed for IFNγ T cell responses specific for overlapping Env
peptide sets.
Results: Robust Env protein expression was confirmed by western blot analysis and recognition of cell surface Env
gp160 by multiple bNAbs. Ad4Env vaccines induced humoral immune responses in rabbits that recognized Env 1086
gp140 and V1V2 polypeptide sequences derived from 1086 clade C, A244 clade AE, and gp70 V1V2 CASE A2 clade
B fusion protein. The immune sera efficiently neutralized tier 1 clade C pseudovirus MW965.26 and neutralized the
homologous and heterologous tier 2 pseudoviruses to a lesser extent. Env-specific T cell responses were also
induced in mice following Ad4Env160 vector immunization.
Conclusions: The Ad4Env vaccine vectors express high levels of Env glycoprotein and induce both Env-specific
humoral and cellular immunity thus supporting further development of this new Ad4 HIV-1 Env vaccine platform in
Phase 1 clinical trials.
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Introduction
The development of an effective AIDS vaccine has
encountered significant barriers including lack of predictive
animal models and absence of well-defined correlates of
protection [1,2]. Of major concern is the failure of four large
efficacy trials, two based on the use of a recombinant HIV-1
Env gp120 (AIDSVAX), a third (“Step” study) based on the use
of a replication-deficient Ad5 vaccine vectors [3-5], and a
fourth, the HVTN 505 trial using a multiclade DNA prime
immunization followed by a replication-deficient multiclade Ad5
boost immunization [6,7]. However, the results of the RV144
ALVAC/AIDSVAX Phase 2b efficacy trial in Thailand showed
an estimated efficacy of 31.2% and suggested that a vaccine to
prevent HIV-1 infection may be closer than previously thought
[1,2,5,8]. However, efficacy was considered modest and
insufficient for the vaccine to be implemented as a public health
measure [9]. Furthermore, the vaccine had no effect on
modifying viral load or CD4+ T cell counts in vaccinated
individuals who became infected. The vaccine components
used in the RV144 trial were administered using a
heterologous prime-boost approach. The priming vaccine was
a recombinant canarypox vector virus (ALVAC), which is
replication-incompetent in humans, expressing Gag, protease
and clade E Env gp120 linked to the transmembrane anchoring
portion of gp41. The boosting vaccine was the same AIDSVAX
B/E gp120 used previously in the AIDSVAX trial in Thailand [5].
Cellular responses were tested in a subgroup of vaccinees with
only minimal level of responses observed. Subsequent
analyses have revealed potential immune correlates of
protection including: 1) V1V2 binding antibodies and 2) CD4+ T
cell responses targeting epitopes within the V2 region [10,11].
Thus, vaccines designed to induce significant levels of Env
gp120-specific V1V2 antibodies and T cell responses may
have improved efficacy against HIV-1 infection. Additionally,
several studies have suggested that a more robust induction of
bNAbs may increase vaccine efficacy and duration. Many viral
vaccines rely on the induction of bNAbs as the primary
correlate of protection [12]. Specifically, for HIV-1, passive
transfer of bNAbs can completely block infection by chimeric
SHIV in non-human primates (NHP) studies [13-16]. The
potential of bNAbs to protect against HIV-1 infections is also
demonstrated by gene-based antibody delivery in humanized
mice and NHPs [17,18].
The recent Phase 2b trials of HIV-1 vaccines support a
prime-boost approach and the inclusion of a HIV-1 Env
glycoprotein. The lack of efficacy in the AIDSVAX trials,
VAX004 and VAX003, suggest a need for greater coverage of
neutralizing antibody and T cell immunity [4,19-22]. The Step
and HVTN 505 trials suggest a need for higher or qualitatively
different T cell responses and a need for an Env antigen (Step)
that induces robust Env-specific antibody responses (HVTN
505). The RV144 trial which employed a poxvirus vector (both
T and B cell immunogens) prime immunization followed by Env
glycoprotein boost immunization appeared to provide ‘some’
low but significant protection against HIV-1 infection.
A concern regarding the possibility of vaccine-induced
enhancement of acquisition of HIV-1 infection also arose out of
the Step trial, since it was confounded by the observation that
there were more HIV-1 infections in the vaccine group than the
placebo group, an unanticipated result [3,23]. The apparent
increase in HIV-1 infections was observed mainly in men, who
were either uncircumcised or who had pre-existing Ad5
neutralizing antibody or both. At the time of the interim analysis
of the Step trial, enrollment in an analogous study (Phambili) in
South Africa with the same vaccine was terminated. Recently,
a long term follow-up of the Phambili study suggested a
possible, but not significant increase in HIV-1 infections in the
vaccine group compared to the placebo [6], but, in this case,
there was no relationship to pre-existing Ad5 neutralizing
antibody titers, or to the sex of the vaccine recipient. Recently,
interim results of the HVTN 505 trial also indicated there was a
non-statistically significant increase in the number of HIV-1
infections among volunteers in the investigational vaccine
group compared to the placebo group, though, this was not
related to Ad5 pre-existing immunity (all participants were
required to by Ad5 seronegative at enrollment) [7]. Although all
three of these studies included a recombinant Ad5 vector in the
vaccine regimen, in the HVTN 505 study, the non-statistically
significant increase in HIV-1 infections in the vaccine group
began to emerge, after the three DNA priming vaccines, but
before the Ad5 booster vaccine, suggesting that something
other than pre-existing Ad5 immunity or an Ad5 vector as a
specific risk factor(s) for potential enhancement. Two of the
three studies demonstrating possible enhancement (Step,
Phambili) did not include an Env antigen. In the third, HVTN
505, transgenes specific for Env were included, but unlike
RV144 there was no Env glycoprotein boost, and antibody
titers, particularly neutralizing antibody to tier 1 viruses, were
low or not detected.
One could speculate in the Step, Phambili, and HVTN 505
trials that vaccine induction of activated immune cells may
increase the targets for HIV-1 infection. By this rationale, any
vaccination or unrelated infection may also increase the
numbers of potential targets and enhance a subject’s
susceptibility to HIV-1 infection. There may be opposing
mechanisms at work following vaccine administration; 1) an
increase of immune cell targets which may augment
susceptibility to HIV-1 infection; and 2) immune responses
induced that neutralize the virus and/or eliminate the virally-
infected cell thereby preventing or controlling infection.
The suggestion of enhancement of HIV-1 virus transmission
in these trials in the presence of minimal Env-specific antibody
responses suggests the need for much more potent vaccine
induction of protective antibody responses. One approach may
be a replicating vector system to generate Env antigen
persistence and thus potentially leading to higher levels of
somatic mutations to generate broad neutralizing antibodies
[24].
The objective of this study is to build upon two observations.
The first is from the RV144 Thai trial, which pointed to
heterologous prime-boost as a potentially successful HIV-1
immunization approach. The second is from our recent Phase
1 clinical trial with an orally administered, replication-competent
Ad4 vectored vaccine for avian (H5) influenza, in which very
high seroprotection and seroconversion were observed with
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oral Ad4-H5HA prime immunization followed by parenteral
inactivated H5HA protein boost immunization [25].
To this end, we have developed HIV-1 candidate vaccines
based on Ad4 recombinant vectors expressing HIV-1 1086
clade C full-length (gp160) Env [26], which may provide a
means to express and present on the cell membrane the
correct conformation of Env appropriate for immunogenicity.
This vaccine was compared with other Ad4Env vectors
expressing gp140 or gp120 which will be secreted from
recombinant vector infected cells. The vaccine was analyzed in
vitro following infection of A549 cells for Env-specific protein
expression and for recognition of cell surface Env by broadly
neutralizing antibodies (bNAbs). Furthermore, the relative
capacity of the three Ad4Env constructs to induce Env-specific
humoral immunity in small animals was evaluated. Env-specific
cellular immunity was evaluated for the Ad4Env160 vector.
The aim of this study was to evaluate recombinant Ad4
vectors encoding HIV env 1086 clade C transgene for Env
glycoprotein expression and capacity to induce Env-specific
immune responses in small animals. These data support
further development of the Ad4 HIV-1 Env vaccine platform in
Phase 1 clinical trials.
Materials and Methods
Ethics Statement
All animal procedures were performed at Explora BioLabs,
San Diego, CA. These facilities are accredited by the American
Association for the Accreditation for Laboratory Animal Care
(AAALAC) and carry appropriate US government assurances
(NIH Assurance #A4487-01, USDA #93-R-0512). Explora
conducts an IACUC review for all proposed animal studies and
approved these studies (rabbit protocol #EB10-033-001,
mouse protocol #EB12-030-001). Studies were conducted in
accordance with the NIH “Guide for the Care and Use of
Laboratory Animals”. Rabbits were allowed to acclimate to the
environment for 7 days and mice for 3 days prior to initiation of
the studies.
Cell Lines
A549 cells were used as a cell substrate for the generation
and growth of the Ad4Env recombinant viruses. The A549 cell
line is a human epithelial lung carcinoma cell line obtained from
ATCC #CCL-185, Manassas, VA [27]. An A549 master cell
bank has been produced at PaxVax for GMP manufacturing
and its potential use as a substrate for vaccines was reviewed
at the September 19, 2012 FDA Advisory Committee on
Vaccines and Related Biologicals Products (VRBPAC)
meeting, where “The committee agreed that there are concerns
with human tumor-derived cell lines but that CBER had
addressed these safety concerns based upon the currently
recommended assays and potential applications of new
technologies” [28].
Construction of Ad4Env Recombinant Viruses
Recombinant Ad4-HIV-1-Env viral plasmids were generated
by homologous recombination in E. coli using a large
adenoviral plasmid and a shuttle plasmid containing env
transgene and flanking Ad4 sequences as previously described
[29]. All env genes were derived from the 1086 clade C isolate
of HIV-1 [26] and inserted such that codon-optimized env
transgene expression is driven by the native adenoviral major
late promoter with an added BGH poly-adenylation signal
sequence (Figure 1). The following amino acid sequence
AKRRVVEREKR was mutated to AKERVVEREKE to prevent
cleavage by furin to gp120 and gp41 glycoproteins.
Homologous recombination and identification of correct clones
were done as described previously [29]. Recombinant
replication competent viruses were generated by transfecting
PacI-linearized Ad4Env plasmid DNA into A549 cells. One day
before transfection, 2 × 106 A549 cells were plated into 100 mm
cell culture dishes (BD Falcon, Franklin Lakes, NJ) in DMEM
(Hyclone, Logan, UT) /10% FBS (Hyclone) and the plates were
incubated at 37 °C in a humidified atmosphere of 5% CO2. The
following day, cells at 70-80% confluence were transfected with
10 µg of linearized Ad4Env DNA using Fugene HD transfection
reagent as per the manufacturer’s instructions (Roche Applied
Sciences, Indianapolis, IN). Two to three days post-
transfection, when cells had reached confluence, the A549
cells were expanded into T-series flasks and incubated at 37
°C in a humidified atmosphere of 5% CO2 until cytopathic effect
(CPE) was observed. Once CPE was observed, generally 7-10
days after transfection, infected cells were harvested and virus
was released using 3 freeze-thaw cycles. The lysate was
clarified by centrifugation at 1,800 × g for 10 min at 4 °C, and
supernatant was collected and the titer estimated by AE-HPLC
[30]. Titered virus was subsequently used for testing of Env
protein expression by western blot analysis and for scale-up in
cellSTACKS® (Corning, Corning, NY).
Site-Directed Mutagenesis to Generate Env160K→N
The shuttle plasmid containing wild-type env160 transgene
and flanking Ad4 sequences was used as a template for site
directed mutagenesis per manufacturer’s instructions (Quick
Change II XL kit, Agilent Technologies, San Diego, CA). Briefly,
forward and reverse primers were designed with mutated
nucleotides and used to amplify the template by PCR. The
template plasmid was digested with Dpn I restriction
endonuclease leaving the newly synthesized unmethylated
nicked PCR product. The product was transformed into E.coli
cells, where the nick was ligated with host repair enzymes. The
resultant plasmid was used in homologous recombination to
produce the pPV-Ad4 Env160K→N plasmid.
Western Analysis to Determine Env Transgene Protein
Expression
A549 cells were infected with 5 × 108 vp/mL of Ad4Env120,
Ad4Env140 and Ad4Env160 recombinant vectors. After two to
three day incubation, the cells were resuspended in RIPA
buffer (Thermo Scientific, USA) supplemented with protease
inhibitors. The cell lysates were mixed with sodium dodecyl
sulfate (SDS) buffer (125 mM Tris-HCl, pH 6.8; 4% SDS; 20%
glycerol; 0.01% bromophenol blue; and 10% beta-
mercaptoethanol) and boiled for 10 minutes. Cell lysates were
then loaded onto a 4-10% polyacrylamide gel. Proteins were
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transferred to nitrocellulose membrane using iBlot gel transfer
device (Life Technologies, USA). The primary detection
antibody was the HIV-1 clade C VRC-C 3B3 mAb (from Dr.
Barton Haynes, [31]). A horseradish peroxidase (HRP)-
conjugated anti-mouse IgG Ab (Southern Biotech, USA) was
used as the secondary antibody. The blots were developed
using the SuperSignal West Femto blotting detection system
(Thermo Scientific, USA).
FACS Staining of Cell Surface Env gp160 Using bNAbs
A549 cells were harvested using 0.25% Trypsin-EDTA from
80-90% confluent T225 flasks and 25 × 106 cells infected in
suspension with 5 × 108 vp/mL of purified Ad4Env160 or
Ad4Env160K→N recombinant virus in 5 mL growth medium
(Dulbecco’s minimal essential medium, high-glucose (DMEM)
containing 10% FBS) for 1 hour at 37 °C with occasional
shaking. The 5 mL suspension was then added to 35 mL
growth medium, transferred to a T225 flask, and incubated
overnight at 37 °C. Eighteen hours after infection, the medium
was removed and A549 cells expressing Env160 or
Env160K→N glycoprotein were harvested by adding 15 mL
FACS buffer [phosphate-buffered saline (PBS), 1% FBS],
scraping the monolayer with a cell scraper, and the cell
suspension transferred to a 50 mL conical tube followed by
centrifugation at 1,200 rpm for 5 minutes to pellet. The cell
pellet was resuspended once in FACS buffer to wash,
centrifuged, and then resuspended in 5 mL blocking buffer
(10% normal goat serum) and incubated on ice for 30 minutes
with occasional shaking. The cells were washed again in FACS
buffer and stained with dilutions of primary monoclonal HIV-1
Env-specific bNAb at 10, 1, 0.1, and 0.01 µg/mL for 30 minutes
at 4 °C. Cells were washed multiple times to remove unbound
antibody and incubated with a 1:100 dilution of R-PE-goat anti-
human IgG F(ab’)2 antibody (Jackson ImmunoResearch, West
Grove, PA) for 30 minutes at 4 °C. The cells were washed
again thoroughly, fixed with 4% paraformaldehyde (BD Cytofix,
Figure 1.  Ad4Env vector design.  The HIV-1 env gene sequence was derived from 1086 clade C and inserted into the Ad4 virus
E3 region. The use of a shuttle plasmid encoding the Env sequence and the Ad4 plasmid to obtain the final vaccine product is
described in Materials and Methods.
doi: 10.1371/journal.pone.0082380.g001
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BD Bioscience, San Jose, CA) for 30 minutes, then acquired
on an Accuri flow cytometer (BD Biosciences). Data were
analyzed using FlowJo analysis software (Treestar Inc.,
Ashland, OR). The bNAbs were kindly provided from several
sources which are indicated in the Acknowledgment section.
Ad4Env120, Ad4Env140, and Ad4Env160 Purified Virus
Production for Animal Studies
Expansion of the recombinant viruses was accomplished
using 10-Chamber cellSTACKS®. A549 cells were seeded (1 ×
108 cells/cellSTACKS®) in culture medium. Cells were infected
when 80 to 90% confluence was achieved with Ad4Env120,
Ad4Env140, or Ad4Env160 viruses at a concentration of 5 ×
108 vp/mL. CellSTACKS® containing the infected cells were
incubated at 37 °C and 5% CO2 until development of 70-80%
CPE, typically after 2 to 3 days incubation. The cells were
removed in lysis buffer, and the expanded virus purified from
the lysate, following clarification, by anion exchange
chromatography and ultrafiltration. Virus identity was confirmed
by sequencing across the insertion point and western blot
analysis with the concentration of virus particles determined by
AE-HPLC [30]. Purified virus was recovered in a Tris-glycerol
formulation buffer and stored at −80 °C.
Immunization Protocol
Female New Zealand White rabbits with body weight of 2 to
4 kg were purchased from Charles River, Wilmington, MA, and
housed in the vivarium facilities at Explora BioLabs, San Diego,
CA. Rabbits were allowed to acclimate to the environment for 7
days prior to initiation of the study and randomized into 5
immunization groups of 3 rabbits per group. Two Ad4Env
vaccine immunizations were given with a one month interval
followed by a recombinant Env gp140 boost immunization two
months following the second vector immunization. Specifically,
rabbits were immunized on days 0 and 28 by the intramuscular
(i.m.) route with 1 × 1011 vp of Ad4Env160, Ad4Env140, or
Ad4Env120 vectors into the quadriceps muscles, with 0.5 mL
delivered in each hind leg (1 mL total volume per dose). It
should be noted that one group of rabbits was also immunized
by the intranasal (i.n.) route with 1 × 1011 vp of Ad4Env140
inoculated into each nare in a 75 µL volume using a pipetman
(150 µL total volume per dose). An Ad4Env vaccine dose
titration was not performed to determine the lowest dose that
was sufficient for inducing transgene-specific immune
responses. Instead, high doses of vaccine were used to
increase the likelihood that immune responses would be
generated and could be assessed. Recombinant Env 1086
clade C gp140 (100 µg) formulated in Rehydragel® (General
Chemical, Parsippany, NJ) as the booster immunization was
given on day 84 by the i.m. route in a total volume of 1 mL. As
a negative control, rabbits were immunized three times with 1 ×
1011 vp of Ad4 wild type (Ad4wt) virus using the same
schedule, i.e., days 0, 28, and 84. As the positive control, 100
µg recombinant Env 1086 clade C gp140 formulated in
Rehydragel® was given three times using the same schedule.
Blood was collected for Env-specific antibody evaluation prior
to immunization and following each immunization; days 0, 28,
84, and 112.
Female C57BL/6 × BALB/c (CB6F1) mice were obtained
from Charles River for vaccine immunizations to evaluate
vaccine induction of Env-specific T cell responses. Three
groups, 6 mice per group, were housed in the vivarium facilities
at Explora BioLabs. Mice were allowed to acclimate to the
environment for 3 days prior to initiation of the study. Mice were
immunized two times on days 0 and 28 with Ad4Env160K→N
(lysine to asparagine modification at position 160 in V2 loop),
Ad4wt, or recombinant Env 1086 clade C gp140 formulated in
MPL/10%Rehydragel® (MPL from InvivoGen, San Diego, 12.5
µg per dose). Specifically, group 1 mice were immunized with 1
× 1010 vp of Ad4Env160K→N in 100 µL by the i.m. route (50 µL
per hind limb). An Ad4Env vaccine dose titration was not
performed to determine the lowest dose that was sufficient for
inducing transgene-specific immune responses. Instead, high
doses of vaccine were used to increase the likelihood that
immune responses would be generated and could be
assessed. Group 2 mice were immunized subcutaneously (s.c.)
at the base of the tail with 10 µg recombinant gp140 in
MPL/10% Rehydragel®, and group 3 immunized i.m. with 1 ×
1010 vp of Ad4wt virus. On day 56, spleens were isolated for
use in the IFNγ ELISPOT assay.
Splenocyte Isolation and T Cell Depletion
Four weeks following the second immunization, mice from
each group were sacrificed, spleens isolated, and splenocytes
prepared for use in the IFNγ ELISPOT assay. Briefly, spleens
were isolated by dissection and placed in 5 mL PRMI-1640
medium containing 10% FBS (R10) and 50 U/mL benzonase
(EMD Biosciences, San Diego, CA). Spleens were expressed
through a 70 micron cell strainer, washed, centrifuged, and
cells resuspended in 1 × RBC lysis buffer (eBioscience, San
Diego, CA). After 5 minutes, the cells were washed with R10-
Benzonase, centrifuged, and splenocytes resuspended in 10
mL R10 medium and counted. Whole splenocytes were
resuspended at a final concentration of 4 × 106 cells/mL. For
CD4+ or CD8+ T cell depletion, Dynabeads Mouse CD4+ or
Mouse CD8+ (Lyt 2) (Life Technologies, Carlsbad, CA) were
used according to the manufacturer’s specifications. Briefly, a
fraction of whole splenocytes were centrifuged, medium
removed, and cell pellets resuspended in Dynabead Isolation
Buffer. Pre-washed resuspended Dynabeads, either CD4+ or
CD8+, were added and incubated with the cells for 30 minutes
at 4 °C on a rotator. The mixture was then placed in a magnet
for 2 minutes. Supernatants were transferred to a new tube and
the cells counted. The depleted splenocytes were then
centrifuged to remove the Isolation Buffer, and resuspended in
R10 medium at final concentration of 4 × 106 cells/mL.
Env-Specific ELISA Assays
Env gp140 ELISA.  High-binding EIA/RIA 92-well
microplates were coated overnight at 4 °C with 100 µL 1 µg/mL
recombinant Env 1086 clade C gp140 antigen. The plates were
washed with 200 µL PBS and blocked for 2 hours at room
temperature (RT) using 200 µL 10% normal goat serum (Life
Technologies, Carlsbad, CA). After washing, serial 1:3 dilutions
of immune serum (100 µL/well) diluted using 10% normal goat
serum were added to the plates and incubated for 2 hours at
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RT. The plates were washed again and wells incubated with a
1:10,000 dilution of horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG (γ-chain specific) secondary detection
antibody (Bethyl Laboratories, Montgomery, TX) for 1 hour at
RT. For detection of antigen-specific signal, the plates were
washed and 100 µL of 3’, 3’ tetramethylbenzidine (TMB single
solution, Life Technologies) added to each well. Color was
allowed to develop for 5 minutes then 100 µL 1N HCl added to
stop the reaction. Microplates were read at 450 nm on a M3
SpectroMax plate reader (Molecular Devices, Sunnyvale, CA).
Data was analyzed using GraphPad Prism analysis software.
Env V1V2 ELISA Assays.  The gp70 V1V2 CASE A2 clade
B fusion protein was used as a coating antigen consists of 96
amino acids of the V1V2 loop domain together with flanking
conserved sequences, joined at the C-terminus of a fragment
consisting of the first 263 amino acids of the murine leukemia
virus (MLV) gp70 protein [32]. AE.A244 and 1086 V1V2 Avi
Tag polypeptides were used for clades E and clade C coating
antigens, respectively. V1V2 Avi Tag polypeptides were
produced as described [33,34]. ELISA plates, 384 well
(Corning Costar), were coated with 50 µL of 2 µg/mL antigen in
0.1 M sodium bicarbonate for 1 hour and then blocked with
assay diluent [PBS containing 4% (w/v) whey protein/15%
Normal Goat Serum, 0.5% Tween-20, and 0.05% Sodium
Azide]. Immune sera were incubated for 90 minutes in three-
fold serial dilutions beginning at 1:50 followed by washing with
PBS/0.1% Tween-20. AP-conjugated goat anti-rabbit
secondary antibody (Sigma) was incubated at 1:3,000 for 1
hour in 30 µL, then washed and detected with 30 µL of CBC
buffer with 2 mM MgCl2 and 1 mg/mL p-NPP [4-Nitrophenyl
phosphate di(2-amino-2-ethyl-1,3-propanediol) salt]. Plates
were read at 405 nm after 45 minutes.
HIV-1 Pseudovirus Neutralization in TZM.bl and A3R5.7
Cells
Virus neutralization was measured using a luciferase-based
assay in TZM.bl or A3R5.7 cells as previously described
[35,36]. Specially, the TZM.bl cell assay was used for
evaluating neutralization of HIV-1 tier 1 pseudovirus
MW965.26. The A3R5.7 assay was used for the tier 2
IMC.LucR viruses Ce1086_B2.LucR.T2A.ecto,
Du151.2.LucR.T2A.ecto, Ce2010_F5.LucR.T2A.ecto,
Ce1176_A3.LucR.T2A.ecto, and Du422.1.LucR.T2A.ecto. The
assay measures the reduction in luciferase reporter gene
expression in TZM.bl following a 48-hour incubation period with
a single round of virus infection, and in A3R5.7 cells following
limited rounds of replication over a 4-day incubation period. In
both assays, the 50% inhibitory dose (ID50) titer was calculated
as the serum dilution that caused a 50% reduction in relative
luminescence units (RLU) compared to the level in the virus
control wells after subtraction of cell control RLU. Calculations
were performed using a validated macro employing a point-
based algorithm with linear interpolation between the two
replicates on either side of 50% RLU reduction.
Measurement of Env-Specific T Cell Responses with an
IFNγ ELISPOT Assay
T cell responses specific for 15-mer peptides from the HIV-1
Consensus clade C Env gp160, the recombinant Env gp140
1086 clade C, and heat-inactivated Ad4 wild type virus (72 °C
for 1 hour) were evaluated using an IFNγ ELISPOT assay. The
complete set of overlapping peptides was obtained from the
NIH AIDS Reagent Program (Catalog Number 9499). Peptides,
dissolved in dimethyl sulfoxide at a concentration of 20 mg/mL,
were combined in sequential order from N- to C-terminus to
generate 8 pools of approximately 25 peptides each. For the
assay, 96-well assay plates (MSIPS4510, Millipore, Bedford,
MA) were coated with 100 µL of 10 µg/mL monoclonal antibody
specific for murine IFNγ (clone AN18, Mabtech, Stockholm) by
incubation overnight at 4 °C. The plates were washed with PBS
and blocked with R10 medium for 1 hour at 37 °C. Erythrocyte-
free mouse splenocytes (4 × 105 per well) were added in
triplicate to wells containing either no antigen, each peptide
pool at a final concentration of 3 µg/mL/peptide, 10 µg/mL of
Env gp140, or 9 × 108 vp/well of heat inactivated Ad4wt virus in
a total volume of 0.2 mL. Plates were incubated for 24 hours at
37 °C. Wells were washed with PBS followed by 1 hour
incubation at RT with 100 µL of 1 µg/mL biotin-conjugated
monoclonal antibody specific for murine IFNγ (clone R4-6A2,
Mabtech) diluted in PBS containing 10% FBS. Plates were
washed again and 100 µL of streptavidin-peroxidase complex
(Mabtech) added to each well. After 1 hour incubation at RT,
the plates were washed thoroughly with PBS followed by the
addition of 100 µL AEC peroxidase substrate solution (Vector
Laboratories Inc., Burlingame, CA) for spot development. The
reaction was stopped after 5 minutes by washing the plate
wells with water. Spots were counted using a CTL S5 Core
plate reader (Cellular Technologies Ltd., Shaker Heights, OH)
and the data recorded as the number of spot forming cells
(SFC) per 1 × 106 splenocytes ± the standard deviation.
Statistics
ELISA.  ED50 titers for ELISA were calculated as the 50%
endpoint response following analysis of the dilution curve using
a 4-parameter logistic curve-fit model. The Student t test was
used to determine significance between groups. A p value of ≤
0.05 was considered significant using unpaired two-tailed
analysis parameters. Calculations and extrapolation of titration
curves were performed using GraphPad Prism analysis
software (version 5.01). In regard to pseudovirus neutralization,
the criterion for a positive response was 3-fold above the
observed background in the pre-bleed sample.
ELISPOT.  The mean and standard deviation of the assay
spot count from triplicate wells were reported. The Student t
test was used to compare the immune response between test
wells and wells receiving ‘no antigen’. A p value of ≤ 0.05 was
used as the indication of a significant response. Additionally, to
be considered a positive response, a minimum of 50 IFNγ SFC
had to be achieved.
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Results
Ad4Env120, Ad4Env140, and Ad4Env160 Recombinant
Virus Generation
The Ad4Env120, Ad4Env140, and Ad4Env160 viruses were
generated in A549 cells. Extraction of the viral DNA and
restriction digestion mapping with several combinations of
enzymes confirmed that the viral genome was intact without
major deletions or insertions (data not shown). PCR
amplification across the E3 region, including the expression
cassette, generated a DNA product of the correct size and
sequencing of the PCR product confirmed the sequence
identity of the transgene and flanking regions (data not shown).
Ad4 env Transgene Expression of gp120, gp140, and
gp160 in A549 Cells
Env glycoprotein expression and secretion were evaluated
by western blot analysis after infection of A549 cells with
Ad4Env120, Ad4Env140, or Ad4Env160 recombinant vectors
(Figure 2). As expected, Env gp120 and gp160 expressed
glycoproteins were detected largely in the supernatant or cell
pellet fractions, lanes 1 and 6, respectively. The Env gp140
expressed glycoprotein was associated with both-supernatant
and cell pellet, lanes 2 and 5, respectively. Recombinant Env
gp140 was used as a positive control, lane 8, which
corresponded in size to the gp140 expressed from the
Ad4Env140 vector.
Cell Surface Recognition of Env160 and Env160K→N
Glycoproteins by bNAbs
A panel of bNAbs recognizing various regions of the Env
glycoprotein including: 1) CD4 binding site (CD4bs); 2)
membrane proximal external region (MPER); 3) V1V2 loops;
and 4) V3 loop were used to evaluate the antigenicity of cell
surface-expressed Env gp160 and Env gp160K→N. A549 cells
were infected with Ad4Env160 recombinant virus, stained with
bNAbs, and evaluated for cell surface Env160 glycoprotein
expression using flow cytometry. Env gp160 expressed on the
surface of A549 cells was recognized by CD4bs-specific
antibodies, including 3BNC117 and NIH 45-46, and the MPER-
specific antibodies 4E10 and 10E8 (Figure 3A). Recognition of
Env gp160 was evident by peak shift when using 0.1 µg/mL
and higher concentrations of bNAbs. However, conformation-
dependent antibodies (PG9, PG16, PGT145, and CH01)
recognizing V1V2 loops were not reactive, even at 10 µg/mL,
the highest concentration of bNAb used. A single amino acid in
the 1086 clade C Env glycoprotein at position 160 (HΧB2
numbering sequence) in the V2 loop was changed by site-
directed mutagenesis from lysine (K) to asparagine (N) to
enable N-linked glycosylation at this site [37]. The recombinant
Ad4 vector expressing Env160K→N was then used to infect
A549 cells, and surface expression of the mutated Env
glycoprotein was now clearly recognized by PG9, PG16, and
PG145 bNAbs (but not CH01) at concentrations of 0.1 µg/mL
and higher (Figure 3B). The mutagenesis did not affect the
binding of CD4bs and MPER-specific bNAbs which retained
reactivity for the Env160K→N glycoprotein. A total of 19 bNAbs
were used to evaluate the antigenicity of Env gp160 and Env
gp160K→N (Table 1). A majority of the bNAbs recognized both
Env gp160 and Env gp160K→N suggesting that both Env
proteins were presented on the infected cell surface in an
appropriate conformation. bNAb reactivity, particularly at lower
antibody concentrations, was not observed when the cells were
infected with Ad4wt virus or when only secondary antibody was
used.
Ad4Env120, Ad4Env140, and Ad4Env160 Recombinant
Virus Production Yields
Ad4Env recombinant viruses were produced and purified to a
scale sufficient for use in small animal immunogenicity studies
(Table 2). It should be noted that the average purified
recombinant virus yield per cell stack (CS) was comparable for
Ad4Env120 and Ad4Env140 viruses, 1.38 × 1013 vp and 1.81 ×
1013 vp, respectively. In contrast, recombinant virus yield per
cell stack for Ad4Env160 virus was approximately 11-fold less,
1.44 × 1012 vp. The lower yield of virus may indicate toxic
effects on the cell substrate when expressing the full-length
Env gp160.
Ad4Env-Induced Humoral Responses in Rabbits
Ad4 recombinant vectors expressing Env gp120, Env gp140,
and Env gp160 glycoproteins were used to immunize rabbits.
Figure 2.  Western blot analysis of env transgene protein
expression.  A549 cells were infected with Ad4Env120,
Ad4Env140 or Ad4Env160 recombinant viruses and harvested
two to three days later. Comparable amounts of each Env
protein (approximately 2 µg) were run on a SDS-PAGE gel and
transferred to nitrocellulose. Env proteins were labelled with a
mouse anti-HIV Env 1086 clade C (VRC-C 3B3) antibody
which was then detected with a goat anti-mouse HRP antibody.
doi: 10.1371/journal.pone.0082380.g002
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Figure 3.  Recognition of cell surface Env 1086 clade C glycoprotein by bNAbs.  A549 cells infected at a concentration 5 × 108
vp/mL of Ad4Env160, (A) and Ad4Env160K→N (B). Cells were harvested 18 hours after infection and flow cytometry performed
using 10, 1.0, 0.1, and 0.01 µg/mL concentrations of bNAb as primary and goat anti-human R-PE as secondary antibody. The
reactivity of each bNAb at the highest concentration against the negative control Ad4wt-infected cells is shown in each panel
(indicated by “wt 10 µg/mL”). Any non-specific background staining shown was not evident at lower concentrations of bNAbs.
Binding of the secondary antibody alone is indicated by “2° Ab only”.
doi: 10.1371/journal.pone.0082380.g003
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Rabbits were immunized twice on days 0 and 28 with the
Ad4Env recombinant viruses, followed by a recombinant Env
gp140 1086 clade C booster immunization formulated in



































PG9 2009 gp120 V1/V2 loops +/- +++
PG16 2009 gp120 V1/V2 loops - +++
PGT145 2011 gp120 V1/V2 loops - +++

















2G12 1994 gp120 Glycan + +
2F5 1993 gp41 MPER - -
4E10 1994 gp41 MPER ++ +++
CH 12 2011 gp41 MPER ++ ++
10E8 2012 gp41 MPER +++ ++
Symbols representing bNAb binding to Env gp160 are depicted as:
+++ = positive high binding as indicated by a histogram shift at 10, 1, and 0.1
µg/mL
++ = medium binding, shifts at 10 and 1 µg/mL
+ = low binding, shift at 10 µg/mL only
+/- = weak binding at 10 µg/mL
- = no binding
doi: 10.1371/journal.pone.0082380.t001
Table 2. Productivity of Ad4Env Recombinant Viruses in
A549 Cells.
Vector Name Infection (vp/mL) CellStacks® Total Yield Yield/C S
Ad4Env160 1 × 108 8 1.16 × 1013 1.44 × 1012
Ad4Env140 1 × 108 2 3.63 × 1013 1.81 × 1013
Ad4Env120 1 × 108 2 2.76 × 1013 1.38 × 1013
doi: 10.1371/journal.pone.0082380.t002
Rehydragel® on day 84 (two months after the last recombinant
vector immunization). Blood was collected on days 0, 28, 84,
112 and then evaluated by ELISA for binding antibodies to Env
gp140 (1086 clade C) and Env V1V2 antigens (1086 clade C,
AE A244 clade AE (clade E Env), and gp70 V1V2 CASE A2
clade B fusion protein, clade B). Note that all groups received
the recombinant Ad4Env vectors by the intramuscular (i.m.)
route with the exception of a single group which was
immunized with the Ad4Env140 vector by the intranasal (i.n.)
route. High levels of Env gp140-specific antibodies were
induced in the rabbits following two recombinant vector
immunizations; geomean ED50 antibody titers, ranging from
1,229 to 11,618, (Day 84, Figure 4A). Following the Env gp140
boost immunization (Day112), increased geomean ED50
antibody titers in the range of approximately 8,317 to 37,473
were elicited. In general, after two immunizations, the Ad4
vector expressing full-length Env160 was more immunogenic
than comparable vectors expressing Env140 or Env120
glycoproteins: Ad4Env160 (11,618 ED50) vs. Ad4Env140 i.n.
(1,906 ED50, p ≤ 0.03); Ad4Env140 (3,293 ED50, p ≤ 0.01); and
Ad4Env120 (1,350 ED50, p ≤ 0.001). A similar pattern was
evident after the booster immunizations with the Env gp140
protein: Ad4Env160 (37,473 ED50) vs. Ad4Env140 i.n. (13,649
ED50, p ≤ 0.05); Ad4Env140 (21,876 ED50, p ≤ 0.03); and
Ad4Env120 (8,317 ED50, p ≤ 0.0001). Ad4Env160 given twice
and followed by the Env gp140 boost immunization (37,473
ED50) was significantly more immunogenic vs. protein given 3
times (16,840 ED50, p ≤ 0.005), respectively. As expected,
Ad4wt virus did not induce Env gp140-specific antibodies.
The higher immunogenicity of Ad4 vectors expressing Env
gp160 relative to gp140 and gp120 was also evident when
evaluating geomean ED50 antibody titers specific for Env gp120
V1V2 antigens (Figure 4B-D). Please note the maximum scale
of ED50 antibody titer is 10,000 for Figure 4B-D. In regard to
binding antibodies specific for 1086 clade C V1V2 polypeptide,
Ad4Env160 vector was significantly more immunogenic than
Ad4Env140 and Ad4Env120 vectors after two recombinant
vector immunizations (day 84) and this difference was
maintained after the recombinant Env gp140 booster
immunization (day 112) (Figure 4B). The following geomean
ED50 antibody titers were induced by day 84: Ad4Env160
(1,213) vs. Ad4Env140 i.n. (326); Ad4Env140 (177, p ≤ 0.015);
Ad4Env120 (79, p ≤ 0.009); and Env gp140 protein (198, p ≤
0.04). Following Env gp140 boost immunization (day 112),
Ad4Env160 (2,784) was again the most potent prime
immunogen: vs. Ad4Env140 i.n. (1,365); Ad4Env140 (883, p ≤
0.02); Ad4Env120 (417, p ≤ 0.006); and Env gp140 protein
(554, p ≤ 0.017).
Also noted, were the differences in Ad4Env immunogenicity
when evaluating induction of cross-reactive geomean ED50
antibody titers against the clade AE (Figure 4C) and clade B
(Figure 4D) V1V2 antigens. In both cases, cross clade-reactive
binding antibodies were more readily induced using the
Ad4Env160 immunogen. Specifically, in the case of reactivity to
AE A244 V1V2 polypeptide, the geomean ED50 antibody titers
induced with the Ad4Env160 prime and Env gp140 1086 clade
C booster immunizations were 874 on day 112 relative to 333
for the Ad4Env140 vector delivered i.n., 306 for the Ad4Env140
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Figure 4.  Immunogenicity of Ad4Env160, Ad4Env140, and Ad4Env120 recombinant viruses in rabbits.  Three rabbits per
group were immunized on days 0 and 28 with each of the Ad4Env 1086 clade C recombinant vectors and booster immunizations
were performed on day 84 with recombinant Env 1086 clade C 140 glycoprotein. Ad4Env vectors were administered by the i.m
route with the exception of one group which also received the Ad4Env140 vector by the i.n. route. Positive control rabbits were
immunized three times with the recombinant Env 1086 clade C gp140 in Rehydragel on days 0, 28 and 84. Negative control rabbits
were immunized three times with Ad4wt virus, i.m., on days 0, 28 and 84; antibody titers were all <50 for this group. Serum samples
were collected on days 0 (pre-vaccine), 28, 84 and 112. The ELISA coating antigens were: (A) Env 1086 clade C 140 glycoprotein;
(B) Env140 1086 clade C V1V2 polypeptide; (C) Env A244 AE strain V1V2 polypeptide; and (D) clade B Env CASE A V1V2 scaffold
fusion protein. For each of the ELISA antigens, statistical analysis using the t-test was performed comparing antibody titers induced
by the Ad4Env160 vector versus titers induced by each of the other Ad4Env vectors or by the Env140 1086 clade C glycoprotein.
Groups with a statistical difference (p ≤ 0.05) in geomean ED50 antibody titers relative to Ad4Env160 vector immunogen are denoted
by an asterisk.
doi: 10.1371/journal.pone.0082380.g004
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vector and 265 for the Ad4Env120 vector (Figure 4C).
Recombinant Env gp140 formulated in Rehydragel® and given
three times induced V1V2-specific ED50 antibody titer of 274 in
only one of three rabbits. The superiority of Ad4Env160 as an
immunogen was also evident in the case of cross-reactive
V1V2-specific antibodies to the gp70 V1V2 CASE A2 clade B
fusion protein (Figure 4D). Specifically, an Ad4Env160
recombinant virus prime followed by an Env gp140 boost (day
112) were capable of inducing geomean ED50 antibody titers
specific for clade B V1V2 fusion protein of 964. Additionally,
Ad4Env160 vector given twice induced geomean ED50 antibody
titers of 373 prior to the Env gp140 boost immunization. In
contrast, using Ad4Env140 i.n., Ad4Env140, and Ad4Env120
immunogens as the priming immunization, followed by the Env
gp140 1086 clade C booster immunization resulted in mean
ED50 antibody titers of 341, 220, and 264, respectively.
Recombinant Env gp140 formulated in Rehydragel® given two
or three times induced cross-reactive ED50 antibody titers of
583 and 182 but in only one of three rabbits. Of note, especially
in the case of cross clade-reactive V1V2 binding antibodies
(Figure 4C and 4D), the Ad4Env160 vector given twice induced
significant responses in three of three rabbits vs. responses in
only one or two rabbits when immunized with the Ad4Env140
and Ad4Env120 vectors.
In summary, full-length Env160 expressed from recombinant
Ad4 vector was a more potent immunogen than either
Ad4Env140 or Ad4Env120 in terms of inducing overall binding
antibodies to Env gp140 and against the homologous Env
V1V2 loop epitopes, and this difference was also observed in
the induction of antibodies to both the clade AE- and B-derived
V1V2 antigens.
The rabbit immune sera were also evaluated for
neutralization of tier 1 and 2 viruses. As shown in Table 3,
recombinant Ad4 vectors expressing Env gp160, gp140 and
gp120 as the prime immunization followed by Env gp140 (1086
clade C) as the boost immunization induced neutralizing
antibody titers specific for MW965.26, a tier 1 clade C virus.
Significant differences in immunogenicity induced was evident
following two recombinant Ad4Env virus immunizations (day
84): geomean ID50 antibody titers were Ad4Env160 (2,868) vs.
Ad4Env140 i.n. (171, p ≤ 0.028); Ad4Env140 (685, p ≤ 0.04);
and Ad4Env120 (230, p ≤ 0.02). The ID50 antibody titers
increased considerably following Env gp140 protein boost
immunization, although differences between vector groups
were not significant: geomean ID50 antibody titers were
Ad4Env160 (11,133), Ad4Env140 i.n. (1,541); Ad4Env140
(2,654); and Ad4Env120 (2,036). In contrast, low but significant
neutralization of the homologous Ce1086_B2.LucR.T2A.ecto
tier 2 clade C virus was most evident with the recombinant
Ad4Env140 vector delivered by either the i.n. or i.m. routes.
Following two Ad4Env vector or Env gp140 immunizations (day
84), the geomean ID50 antibody titer values were the following:
Ad4Env160 (22); Ad4Env140 i.n. (71); Ad4Env140 (50);
Ad4Env120 (40); and Env gp140 (38). Rabbits immunized with
the Ad4wt virus, as expected, did not induce immune sera
capable of neutralizing the Ce1086 tier 2 virus. The Ad4Env140
vaccine also induced, in three of three rabbits, low but
significant neutralization of the heterologous clade C
Du151.2.LucR.T2A.ecto virus in the range of 37 to 69
(geomean, 46) ID50 antibody titer following two vector
immunizations, day 84. The other Ad4Env vectors and Env
gp140 protein also induced neutralization in the same range
but the neutralization was less consistent and typically
observed for only one or two rabbit immune sera. The rabbit
immune sera were evaluated for neutralization activity against
three additional tier 2 clade C viruses; Ce1176.LucR.T2A.ecto,
Ce2010.LucR.T2A.ecto, and Du422.1.LucR.T2A.ecto.
Neutralization of Ce1176.LucR.T2A.ecto virus was not
detected (data not shown). However, sporadic neutralization of
Ce2010.LucR.T2A.ecto, and Du422.1.LucR.T2A.ecto viruses,
in the range of 40 to 99 ID50 antibody titer, was observed
following two Ad4Env vector (Env140 or Env120)
immunizations and an Env gp140 boost immunization but
typically for only one of three rabbits (data not shown).
Additionally, Ce2010.LucR.T2A.ecto and
Du422.1.LucR.T2A.ecto tier 2 virus neutralization was not
observed when immune sera were induced with either
Ad4Env160 vector prime immunization followed by Env gp 140




Groups of mice were immunized two times with either, the
recombinant Ad4Env160K→N virus, Ad4wt virus, or
recombinant Env gp140 formulated in MPL/Rehydragel®.
Splenocytes were obtained for evaluating cellular immunity
using an IFNγ ELISPOT assay and overlapping Env
(consensus clade C) peptide sets, recombinant Env gp140,
and heat-inactivated Ad4wt virus as antigens. Following
Ad4Env160K→N vector immunization, significant Env-specific
cellular responses were induced to several regions of the Env
molecule as denoted by reactivity to peptide pools 1, 6, and 8
in the range of 150 to 370 IFNγ SFC per 1 × 106 whole
splenocytes (Figure 5A). Pools 1, 6, and 8 contain peptides
from the gp120, gp41, and cytoplasmic tail regions of Env
glycoprotein, respectively. When specific T cell populations
were depleted from total splenocytes, pool 1 responses were
shown to be primarily CD4+ T cell-specific (Figure 5B) while
pools 6 and 8 were primarily CD8+ T cell-specific (Figure 5C).
Ad4Env160K→N and Ad4wt viruses induced primarily vector-
specific CD4+ T cells (Figure 5B). The recombinant Env gp140
immunogen (rgp140) did not induce significant T cell
responses.
Discussion
An HIV-1 vaccine strategy that induces durable, protective
humoral and cellular immunity has yet to be developed. To
address this goal, we have built on the modest success of the
RV144 Thai trial and our clinical experience with the Ad4-H5-
Vtn influenza vector [25] to evaluate a heterologous prime-
boost strategy for an HIV-1 vaccine consisting of an oral
replication-competent Ad4-HIV-1-Env recombinant vector
prime followed by a recombinant Env glycoprotein boost. Our
hypothesis is that for induction of a protective immune
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response, an Env-based HIV-1 vaccine is required, along with
a Gag-based internal protein component. Furthermore, the
prolonged intracellular presentation in GI mucosal cells through
delivery by an oral replicating vector followed by systemic
protein boosting is a logical scientific approach. The safety and
immunogenicity of the replication-competent, orally
administered Ad4 vector technology has recently been
documented in a H5 influenza Phase 1 study, and this system
may provide a potential means to express and present on the
cell membrane the correct conformation of Env glycoprotein
required for induction of protective immune responses. It
should be noted that the human Ad4 vaccine vectors
expressing HIV-1 Env described in this paper do not carry out
productive infections in cells of nonhuman origin but, similar to
defective Ad5 vectors, they will infect cells from multiple
species including mice, rabbits, and many species of NHPs,
and these cells will effectively support transcription and
translation of both Ad viral proteins and foreign transgenes.
The full immunological benefits of the Ad4 replication-
competent vector as a vaccine can only be evaluated in
humans where virus replication would likely result in infection of
more cell types and amplification of the amount of transgene
protein delivered to the immune system.
In this study, we generated Ad4 recombinant constructs
encoding HIV-1 Env 1086 clade C glycoproteins. Following
infection of A549 cells in vitro, env transgene protein
expression was confirmed by western blot and recognition of
cell surface Env160 glycoprotein by bNAbs. Interestingly, we
were able to acquire additional bNAb reactivity by engineering
a specific amino acid change (K→N at position 160) in the Env
gp120 V2 sequence. This amino acid change enabled binding
by conformation-dependent bNAbs, PG9, PG16, and PG145.
Whether increased Env glycoprotein antigenicity will translate
into augmented immunogenicity in vivo in humans is not
known. Immunogenicity of the recombinant Ad4Env vectors
was demonstrated by induction of Env-specific antibody and
cellular responses in rabbits and mice, respectively. Several
key aspects of vaccine immunogenicity were observed during
the study: 1) magnitude of Env-specific humoral
immunogenicity was generally dependent on env transgene
length with gp160> gp140> gp120; 2) antibodies specific for
V1V2 peptide were induced; and 3) induction of Env-specific
cellular immunity was also accomplished. In regard to induction
of cellular immunity, it should be noted that we evaluated
responses following recombinant Ad4Env vector immunization
only. It is not known whether a recombinant Env protein boost
immunization would have augmented the immune responses
and/or changed the CD4+ and CD8+ T cell profile. Interestingly,
in the case of tier 2 virus neutralization, the AdEnv140 vector
was more immunogenic than the Ad4 vector expressing the
Table 3. Neutralization of Tier 1 and 2 Clade C Viruses.
  MW965.26
a) Ce1086_B2.LucR.T2A.ectob) Du151.2.LucR.T2A.ectoc)  
  Day Day Day  
Immunogen Rabbit # 0 28 84 112 0 28 84 112 0 28 84 112  
Ad4Env160 1 --d) 37e) 2964 5250 -- 22 -- -- 23 25 22 32  
 2 -- 45 1771 10308 -- -- 24 29 -- 22 38 24  
 3 -- 92 4493 25501 -- 27 21 37 26 48 24 30  
Ad4Env140 (i.n.) 1 -- 27 399 5014 -- -- 34 117 23 23 35 105  
 2 -- 30 624 4831 -- 77 413 923 74 23 39 83  
 3 -- -- -- 151 -- -- 25 56 44 27 -- 99  
Ad4Env140 1 -- -- 535 2480 -- -- 29 39 -- 29 39 76  
 2 -- 235 1105 3773 -- -- 108 488 -- 22 37 34  
 3 -- 24 534 1998 -- 26 40 74 -- 23 69 38  
Ad4Env120 1 -- -- 115 1758 -- -- 47 47 28 34 38 39  
 2 -- 33 452 2927 -- 25 43 111 -- 23 25 26  
 3 -- 42 110 1641 -- 21 32 26 20 34 34 45  
Ad4wt 1 -- -- -- -- -- -- -- -- -- -- -- --  
 2 -- -- -- 33 -- -- -- -- -- 33 -- --  
 3 -- -- -- -- -- -- -- -- -- -- -- --  
Env gp140 1 -- 25 486 2766 -- 37 58 34 -- 21 22 26  
 2 -- -- 235 1742 -- -- 34 31 -- 21 -- --  
 3 -- -- 205 810 -- -- 28 -- -- -- 25 28  
a) Tier 1 clade C pseudovirus
b) Tier 2 clade C homologous infectious Renilla luciferase-expressing reporter virus
c) Tier 2 clade C heterologous infectious Renilla luciferase-expressing reporter virus
d) '--' = <20, ID50 antibody titer
Values are the serum dilution at which relative luminescence units (RLUs) were reduced 50% vs. virus control wells (no test sample)
e) Values in bold type scored positive for neutralization based on the criterion of >3 times the observed background in the pre-bleed (day 0)
doi: 10.1371/journal.pone.0082380.t003
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full-length Env 160 glycoprotein. This is in contrast to
neutralization of the tier 1 MW965.26 pseudovirus where the
Ad4Env160 vector was the superior immunogen. Additional
Ad4Env constructs are being generated to follow-up on this
observation and generate vaccines that potentially improve
upon neutralization of tier 2 viruses. In addition to Env length,
several other variables will be addressed, individually and in
various combinations, regarding their potential to improve Env-
specific antibody responses including: 1) state of furin cleavage
site, i.e., mutated to prevent cleavage vs. wild type; 2)
exogenous vs. endogenous promoters to drive Env transgene
expression; and 3) K→N mutation at position 160 in the V2
loop vs. wild type.
These studies would suggest that development of a vaccine
product expressing a membrane-bound full-length Env gp160
may be preferable vs. secreted gp140 or gp120 in regard to
induction of Env-specific antibodies. In regard to cellular
immunity, robust Env-specific T cell responses were elicited
following immunization of mice with the Ad4Env160K→N
vector. Significant IFNγ responses were induced, in part, to the
cytoplasmic tail (CT) (pool 8) and these responses may not be
realized using either Ad4Env140 or Ad4Env120 vaccines which
lack the CT. Whether the CT-specific T cell responses will have
an added benefit above T cell responses that are induced
specific for gp140 or gp120 is not known. The challenge of
advancing the Ad4Env160 vaccine was witnessed in the
context of virus production where Ad4Env160 was
approximately 10-fold less productive vs. AdEnv140 and
Ad4Env120 viruses. Diminished virus yield may be attributed to
cytopathic effects of the Env cytoplasmic tail region [38-41]. In
studies outside the scope of this report, we generated
recombinant Ad4 vectors expressing Env with truncations of
the cytoplasmic tail but still retain the transmembrane region.
These Ad4 recombinant vectors express membrane bound
gp150 (40 amino acids of CT remain; 118 amino acids were
deleted) and gp145 (4 amino acids of CT remain; 154 amino
acids were deleted) (Alexander et al., unpublished). The
Ad4Env150 and Ad4Env145 recombinant viruses were
approximately 5-fold more productive in virus yield vs.
Ad4Env160 virus in A549 cells and thus provide an attractive
Figure 5.  Ad4Env160K→N vector-induced Env-specific cell-mediated immunity in mice.  C57BL/6 × BALB/c F1 (CB6F1) mice
(6 animals/group) were immunized two times, days 0 and 28, with Ad4Env160K→N recombinant virus, Ad4wt virus, and
recombinant Env gp140 (rgp140). On day 56 the mice were sacrificed and splenocytes pooled and tested in an IFNγ ELISPOT.
Whole splenocytes (A), CD4+ (B), and CD8+ (C) T cells were evaluated. 15-mer peptides from the HIV-1 consensus clade C Env
gp160 sequence, Env gp140 1086 clade C protein, and heat denatured Ad4wt virus were used as target antigens.
doi: 10.1371/journal.pone.0082380.g005
Development of an Ad4 HIV-1 Env Clade C Vaccine
PLOS ONE | www.plosone.org 13 December 2013 | Volume 8 | Issue 12 | e82380
path for Ad4Env vaccine development (Alexander et al.,
unpublished). Potentially, Ad4Env160 vaccine yield could be
improved by suppressing Env160 transgene expression during
vaccine production. Wang demonstrated that the yield of
adenoviral vector particles was increased 10-fold in a
packaging cell line with stable production of a short hairpin
RNA (shRNA) that can silence the transgene vs. a cell
substrate not expressing shRNA [42].
Of note was the capacity of the Ad4Env vaccines to induce
V1V2 peptide-specific binding antibodies to clades C, AE, and
B. This immunogenicity characteristic is likely to be important
for HIV-1 vaccine development, in part, due to the identification
of V1V2 peptide-specific antibodies as a correlate of decreased
transmission risk in the RV144 study [11,43,44]. The V1V2 loop
has a number of features that may be important during initial
events of virus infection. It has a highly conserved length
among early (transmitted/founder) isolates and escape from
neutralizing antibodies is associated with increased V1V2
length and glycosylation [45,46]. Also, V2 loop contains a
potential α4β7 integrin-binding motif that may promote infection
of lymphocytes localized at mucosal tissues [47,48].
Karasavvas et al., using peptide microarray analysis, ELISA,
and Biacore analyses, demonstrated that the immunogens
used in the RV144 trial induced antibodies to the V2 loop of
gp120 from diverse HIV-1 subtypes [43]. In addition, from
analysis of RV144 samples, Rolland et al., reported that
mutations that select against, or sieve HIV-1 breakthrough
infections contain mutations at positions 169 and 181 in V2
[44]. Several other investigators have indentified the V1V2 loop
as a target for bNAbs such as PG9 and PGT145 that engage
V1V2 and neutralize approximately 80% of HIV-1 isolates
[37,49,50]. Taken together, these studies suggest that vaccines
designed to induce V1V2-specific antibodies higher than
observed in the RV144 trial may have better potential to protect
against HIV-1 infection [11].
It is generally thought that a HIV-1 vaccine based in part on a
neutralizing antibody response would be beneficial [51,52]. In
the study reported herein, neutralization of the tier 1 clade C
virus, MW965.26, was readily accomplished with the Ad4Env
vectors. Lower, but significant, neutralization of homologous
tier 2, clade C (Ce1086_B2.LucR.T2A.ecto) and heterologous
tier 2, clade C (Du151.2.LucR.TwA.ecto) viruses was also
observed. It has been difficult to elicit potent and cross-reactive
neutralizing antibody responses by immunization with Env-
based vaccine candidates [53]. This difficulty may be due to
immune dominance of gp120 variable regions, glycan
occlusion, and/or inability of germline versions of the bNAbs to
bind Env [50,54-59]. Thus, vaccine efforts to date have failed to
address the tier 2 phenotype [36,51,52]. Neutralization of
several tier 1 viruses was detected in the RV144 trial, but not
tier 2 viruses, which suggest that modest efficacy observed in
the trial was mediated by other immune responses, either
alone or in combination with tier 1 neutralizing antibodies [35].
To improve upon vaccine induction of more potent broadly
neutralizing antibodies, several approaches have been
suggested including: 1) B-cell-lineage vaccine design [60-62];
and 2) structure-guided vaccine design [53,63-66].
Of interest in regard to vaccine development, is the effect of
pre-existing Ad4 immunity on vaccine potency. This is relevant
since the overall prevalence for Ad4 neutralizing antibodies is
approximately 30% among unimmunized US Army Trainees
[67]. We evaluated the effects of pre-existing Ad4 immunity in a
Phase 1 trial where subjects (approximately 30% with pre-
existing Ad4 neutralizing antibody) received a recombinant Ad4
vaccine expressing avian influenza H5 hemagglutinin [25]. At
high vaccine doses of 109-1011 viral particles (107-109 infectious
units), hemagglutinin-specific cellular responses and priming
for HAI antibody responses were comparable in Ad4
seronegative and seropositive subjects. Thus, these results
suggest that higher doses of vaccine may overcome the effects
of pre-existing Ad4 immunity.
Ad4 recombinant vectors expressing HIV-1 (Env and mosaic
Gag) immunogens will be evaluated in a Phase 1 safety and
immunogenicity trial beginning in October, 2013. Together with
the completed Ad4-H5-Vtn influenza Phase 1 trial these data
may potentially support use of an Ad4 replicating vector system
for use in conjunction with newly developed HIV-1
immunogens.
In summary, we have evaluated several pre-clinical
properties of the Ad4Env vector vaccine. These data support
further evaluation of these new vaccines and if warranted,
Phase 1 clinical trial evaluation.
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